Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Restructuring Costs (2022 - 2024)

InMed Pharmaceuticals has reported Restructuring Costs over the past 3 years, most recently at $23282.0 for Q2 2024.

  • For Q2 2024, Restructuring Costs rose 128.69% year-over-year to $23282.0; the TTM value through Jun 2024 reached -$37961.0, changed N/A, while the annual FY2024 figure was $80513.0, 42.73% up from the prior year.
  • Restructuring Costs for Q2 2024 was $23282.0 at InMed Pharmaceuticals, up from $9768.0 in the prior quarter.
  • Over five years, Restructuring Costs peaked at $44042.0 in Q4 2022 and troughed at -$81147.0 in Q2 2023.
  • A 3-year average of $5753.8 and a median of $16709.0 in 2023 define the central range for Restructuring Costs.
  • Biggest five-year swings in Restructuring Costs: plummeted 76.99% in 2023 and later skyrocketed 128.69% in 2024.
  • Year by year, Restructuring Costs stood at $44042.0 in 2022, then plummeted by 76.99% to $10136.0 in 2023, then surged by 129.7% to $23282.0 in 2024.
  • Business Quant data shows Restructuring Costs for INM at $23282.0 in Q2 2024, $9768.0 in Q1 2024, and $10136.0 in Q4 2023.